Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Takeda’s dengue vaccine receives EC approval

The decision follows a positive recommendation for Qdenga from the CHMP in October

- PMLiVE

Exact Sciences highlights impact of precision oncology portfolio on breast cancer treatment

Data presented at SABCS 2022 supports the company’s cancer diagnostics portfolio

- PMLiVE

FDA approves updated COVID-19 boosters for children aged from six months

The Moderna and Pfizer/BioNTech boosters both target the BA.4/BA.5 omicron subvariants

- PMLiVE

New study links hearing restorative devices to slower rate of memory decline

The use of hearing aids and cochlear implants reduced long-term cognitive decline by 19%

- PMLiVE

PMEA 2022: a celebration of excellence in healthcare marketing

Hosted by Mike Bushell, this year’s event was held at the Sheraton Grand London Park Lane

- PMLiVE

Pharma’s vital role in sustainability and corporate social responsibility

Pharma is in the spotlight as tough questions about sustainability commitments continue to arise

How to Increase Engagement During Virtual Events

Tip #3 - Keep it simple! Check our top 10 tips to increase engagement during virtual events: https://www.impetusdigital.com/2021/03/25/top-10-tips-to-increase-engagement-during-virtual-events/

Impetus Digital

- PMLiVE

What Does Net Promoter Score Offer in the Evaluation of Continuing Medical Education?

Net promoter Score (NPS) has been used in many fields, such as software, clinical care, and websites, as a measure of customer satisfaction since 2003. With a single question, NPS...

Medscape Education

- PMLiVE

Pfizer’s RSV vaccine candidate accepted for FDA priority review for use in older adults

A phase 3 study showed the vaccine was 85.7% effective in those with three or more symptoms

- PMLiVE

Enzyvant and Altavant announce merger to accelerate rare disease therapies

The combined company is in the process of developing in-house manufacturing

- PMLiVE

Summit Therapeutics partners with Akeso in deal worth $5bn

Summit will receive rights to develop and commercialise the bispecific antibody ivonescimab

- PMLiVE

NHS Digital Health Check begins trial to ease pressure on services

The digital service could prevent around 1,600 heart attacks and strokes per year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links